Trial summary
To validate the usability and safety of the Liberty Analyser. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- Entia Liberty
- Type of treatment
- Medical device
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 1 Mar 2024to 30 Jun 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults with a diagnosis of solid tumour cancer, who are currently undergoing systemic anti-cancer therapy
Who may be able to join
- Undergoing systemic anti-cancer therapy (SACT)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2 at enrolment
- Adequate English language skills (not requiring a translator) to participate in participant training and use the Entia Liberty analyser
- Patients capable of providing written informed consent
Who cannot join
- History or current diagnosis of haematological malignancy
- Patients with eyesight or hearing limitations or other disabilities that preclude the use of the Entia Liberty analyser or participation in training
- Inadequate use and understanding of the English language, requiring a translator
About this study
To validate the usability and safety of the Liberty Analyser.
- Conditions
- Cancer
- Being tested
- Entia Liberty
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Entia LibertyDevice
Home monitoring
What is being measured
The primary outcome is the main question the study is designed to answer.
The Entia Liberty Analyser is easy to use
Users can easily carry out a test using the Entia Liberty Analyser
Measured: Through study completion, 1 day
The Entia Liberty Analyser is safe to use
Results obtained using the Entia Liberty Analyser are valid and reliable
Measured: Through study completion, 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2023
- Study start1 Mar 2024 (estimated)
- Primary completion30 Jun 2024 (estimated)
- Study completion30 Jun 2024 (estimated)
Why it stopped: Change in trial pipeline. Study no longer required.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Entia Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06134245
- Sponsor's protocol ID
- IRAS ID: 336920
- Acronym
- HOUSE
- Status last verified
- Sep 2026
- First submitted
- 8 Nov 2023
- Last updated
- 11 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- HOme USability Evaluation
- ClinicalTrials.gov ID
- NCT06134245
- Acronym / sponsor ID
- HOUSE / IRAS ID: 336920
- Conditions
- Cancer
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: Change in trial pipeline. Study no longer required.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Entia LtdIndustry (pharma, biotech, devices)
- Study start
- 1 Mar 2024 (estimated)
- Primary completion
- 30 Jun 2024 (estimated)
- Study completion
- 30 Jun 2024 (estimated)
- First posted
- 18 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To validate the usability and safety of the Liberty Analyser.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults with a diagnosis of solid tumour cancer, who are currently undergoing systemic anti-cancer therapy
Key inclusion criteria (4 listed)
- Undergoing systemic anti-cancer therapy (SACT)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2 at enrolment
- Adequate English language skills (not requiring a translator) to participate in participant training and use the Entia Liberty analyser
- Patients capable of providing written informed consent
Key exclusion criteria (3 listed)
- History or current diagnosis of haematological malignancy
- Patients with eyesight or hearing limitations or other disabilities that preclude the use of the Entia Liberty analyser or participation in training
- Inadequate use and understanding of the English language, requiring a translator
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Entia LibertyHome monitoring | Device | – |
Primary outcome
The Entia Liberty Analyser is easy to use
Time frame: Through study completion, 1 day
Users can easily carry out a test using the Entia Liberty Analyser
The Entia Liberty Analyser is safe to use
Time frame: Through study completion, 1 day
Results obtained using the Entia Liberty Analyser are valid and reliable
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Cancer
RecruitingPhase 1
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
Myeloproliferative Neoplasms (MPNs)
Recruiting
Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC
Bladder Cancer
RecruitingPhase 2
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
RecruitingPhase 1
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
B-cell Mediated Autoimmune Disorders
RecruitingPhase 3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Entia Ltd.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Entia Liberty Analyser is easy to use (time frame: Through study completion, 1 day). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.